Related Experiment Videos
Sarcoidosis associated with interferon-alpha therapy for chronic hepatitis C
Dimitrios Papaioannides1, Marianthi Fotinou, Panagiotis Korantzopoulos
1Department of Medicine, Arta Hospital, Arta, Greece. dipaio@otenet.gr
Summary
Recombinant interferon-alpha (IFN-alpha) treatment for chronic hepatitis C may trigger sarcoidosis in some patients. Monitoring for sarcoidosis symptoms during and after IFN-alpha therapy is recommended.
Area of Science:
- Hepatology
- Pulmonology
- Immunology
Background:
- Recombinant interferon-alpha (IFN-alpha) is a standard therapy for chronic hepatitis C.
- Pulmonary side effects associated with IFN-alpha are considered rare.
- Few cases of sarcoidosis linked to IFN-alpha treatment for hepatitis C have been documented.
Observation:
- A 52-year-old female patient with chronic hepatitis C developed sarcoidosis during IFN-alpha therapy.
- Sarcoidosis diagnosis was confirmed via chest imaging, elevated serum angiotensin-converting enzyme (ACE) levels, and lymph node biopsy histology.
- The patient experienced spontaneous remission of sarcoidosis after discontinuing IFN-alpha treatment.
Findings:
- IFN-alpha therapy may precipitate or exacerbate sarcoidosis in genetically predisposed individuals.
- The case highlights a potential iatrogenic cause of sarcoidosis.
- Early detection and intervention are crucial for managing IFN-alpha-induced sarcoidosis.
Implications:
- Healthcare providers should be vigilant for sarcoidosis symptoms in patients undergoing IFN-alpha treatment for chronic hepatitis C.
- Monitoring for sarcoidosis manifestations during and post-therapy is essential.
- This association warrants further investigation into the immunological mechanisms linking IFN-alpha and sarcoidosis development.